Log in

Halozyme Therapeutics Stock Price, Forecast & Analysis (NASDAQ:HALO)

$18.91
+0.42 (+2.27 %)
(As of 11/16/2019 08:00 AM ET)
Today's Range
$18.40
Now: $18.91
$19.05
50-Day Range
$14.84
MA: $15.86
$18.88
52-Week Range
$13.24
Now: $18.91
$19.05
Volume3.88 million shs
Average Volume2.45 million shs
Market Capitalization$2.77 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.78
Halozyme Therapeutics, Inc, a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:HALO
CUSIP40637H10
Phone858-794-8889

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$151.86 million
Book Value$1.67 per share

Profitability

Net Income$-80,330,000.00

Miscellaneous

Employees281
Market Cap$2.77 billion
Next Earnings Date2/20/2020 (Estimated)
OptionableOptionable

Receive HALO News and Ratings via Email

Sign-up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter.


Halozyme Therapeutics (NASDAQ:HALO) Frequently Asked Questions

What is Halozyme Therapeutics' stock symbol?

Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."

How were Halozyme Therapeutics' earnings last quarter?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) posted its quarterly earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.05. The biopharmaceutical company had revenue of $46.20 million for the quarter, compared to analysts' expectations of $54.96 million. Halozyme Therapeutics had a negative net margin of 19.73% and a negative return on equity of 15.76%. The business's quarterly revenue was up 80.5% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.19) earnings per share. View Halozyme Therapeutics' Earnings History.

When is Halozyme Therapeutics' next earnings date?

Halozyme Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for Halozyme Therapeutics.

What price target have analysts set for HALO?

5 brokers have issued 12 month target prices for Halozyme Therapeutics' stock. Their forecasts range from $16.00 to $27.00. On average, they expect Halozyme Therapeutics' share price to reach $20.80 in the next year. This suggests a possible upside of 10.0% from the stock's current price. View Analyst Price Targets for Halozyme Therapeutics.

What is the consensus analysts' recommendation for Halozyme Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Halozyme Therapeutics.

What are Wall Street analysts saying about Halozyme Therapeutics stock?

Here are some recent quotes from research analysts about Halozyme Therapeutics stock:
  • 1. According to Zacks Investment Research, "Halozyme has promising collaboration deals related to its ENHANZE technology with several small and large pharma companies. These deals generate the majority of revenues for the company. Blockbuster drugs like Herceptin and Rituxan use ENHANZE for subcutaneous administration, which boosts Halozyme’s royalties. Development of subcutaneous formulation of another blockbuster drug, Darzalex is encouraging. Restructuring initiatives following failure of PEGPH20 is also encouraging. Halozyme’s shares have outperformed the industry so far this year. However, the company’s dependence on collaboration partners for revenues remains a concern. Rising competition for partnered drugs is also a concern. Estimates have been stable ahead of Q3 earnings. The company has a positive record of earnings surprise in the recent quarters." (11/7/2019)
  • 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $24 PT per share on HALO. Halozyme reported 1Q19 revenues of $57M, which were below our and FactSet consensus estimates of $62M and $69M, respectively. Additionally, the company ended 1Q19 with cash of ~$329M, and we model current cash and projected ENHANZE royalties to fund HALO through key value-creating milestones. During 1Q19, royalty revenues declined by 14% YoY, mainly due to lower sales of Herceptin SC in Europe, which were partially offset by higher sales of RITUXAN HYCELA versus 1Q18." (5/8/2019)

Has Halozyme Therapeutics been receiving favorable news coverage?

News articles about HALO stock have been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Halozyme Therapeutics earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Halozyme Therapeutics.

Are investors shorting Halozyme Therapeutics?

Halozyme Therapeutics saw a decrease in short interest in the month of October. As of October 31st, there was short interest totalling 7,260,000 shares, a decrease of 7.3% from the September 30th total of 7,830,000 shares. Based on an average daily trading volume, of 981,000 shares, the days-to-cover ratio is currently 7.4 days. Approximately 5.4% of the shares of the stock are short sold. View Halozyme Therapeutics' Current Options Chain.

Who are some of Halozyme Therapeutics' key competitors?

What other stocks do shareholders of Halozyme Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Micron Technology (MU), Allergan (AGN), Aegean Marine Petroleum Network (ANW) and Transocean (RIG).

Who are Halozyme Therapeutics' key executives?

Halozyme Therapeutics' management team includes the folowing people:
  • Dr. Helen I. Torley, Pres, CEO & Director (Age 56)
  • Ms. Laurie D. Stelzer, Sr. VP & CFO (Age 51)
  • Mr. Harry J. Leonhardt, Sr. VP, Gen. Counsel & Corp. Sec. (Age 62)
  • Dr. Dimitrios Chondros, Chief Medical Officer & Sr. VP (Age 54)
  • Mr. Benjamin J. Hickey, Sr. VP & Chief Commercial Officer (Age 44)

Who are Halozyme Therapeutics' major shareholders?

Halozyme Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Eagle Asset Management Inc. (1.05%), Fisher Asset Management LLC (0.80%), Carillon Tower Advisers Inc. (0.72%), California Public Employees Retirement System (0.20%), Alps Advisors Inc. (0.20%) and Rhumbline Advisers (0.15%). Company insiders that own Halozyme Therapeutics stock include Dimitrios Chondros and Randal J Kirk. View Institutional Ownership Trends for Halozyme Therapeutics.

Which major investors are selling Halozyme Therapeutics stock?

HALO stock was sold by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, Russell Investments Group Ltd., Mackay Shields LLC, Janney Montgomery Scott LLC, Alps Advisors Inc., Hancock Whitney Corp, Coastal Investment Advisors Inc. and Taylor Wealth Management Partners. View Insider Buying and Selling for Halozyme Therapeutics.

Which major investors are buying Halozyme Therapeutics stock?

HALO stock was bought by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Carillon Tower Advisers Inc., California Public Employees Retirement System, First Trust Advisors LP, Nisa Investment Advisors LLC, Fisher Asset Management LLC, Synovus Financial Corp and Rhumbline Advisers. View Insider Buying and Selling for Halozyme Therapeutics.

How do I buy shares of Halozyme Therapeutics?

Shares of HALO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Halozyme Therapeutics' stock price today?

One share of HALO stock can currently be purchased for approximately $18.91.

How big of a company is Halozyme Therapeutics?

Halozyme Therapeutics has a market capitalization of $2.77 billion and generates $151.86 million in revenue each year. The biopharmaceutical company earns $-80,330,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Halozyme Therapeutics employs 281 workers across the globe.View Additional Information About Halozyme Therapeutics.

What is Halozyme Therapeutics' official website?

The official website for Halozyme Therapeutics is http://www.halozyme.com/.

How can I contact Halozyme Therapeutics?

Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-794-8889 or via email at [email protected]


MarketBeat Community Rating for Halozyme Therapeutics (NASDAQ HALO)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  400 (Vote Outperform)
Underperform Votes:  363 (Vote Underperform)
Total Votes:  763
MarketBeat's community ratings are surveys of what our community members think about Halozyme Therapeutics and other stocks. Vote "Outperform" if you believe HALO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HALO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/17/2019 by MarketBeat.com Staff

Featured Article: What is the QQQ ETF?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel